The Center for Biosimilars® recaps the top news for the week of November 26, 2018.
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 26.
Number 4: The United Kingdom’s National Health Service announced that it completed negotiations this week over using the best-value adalimumab product. Under the new plan, it will save 300 million pounds of its current 400 million pounds per year spending on adalimumab.
Number 3: A newly proposed rule from CMS would allow plans to make broader use of prior authorization and step therapy for drugs— including drugs in protected classes­– that are covered under Medicare Part D.
Number 2: The European Commission, in conjunction with the Organization for Economic Co-operation and Development, released its annual Health at a Glance report which highlights the need for and value of generic and biosimilar products in Europe.
Number 1: The FDA approved Celltrion and Teva’s rituximab biosimilar this week, to be sold as Truxima.
Finally, last week, our e-newsletter asked if you agree that anti-biosimilar campaigns in the United States foster negative perceptions of biosimilars.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.